These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37094997)

  • 1. Treatment With Erythropoietin for Patients With Optic Neuritis: Long-term Follow-up.
    Küchlin S; Ihorst G; Grotejohann B; Beisse F; Heinrich SP; Albrecht P; Ungewiss J; Wörner M; Hug MJ; Wolf S; Diem R; Lagrèze WA;
    Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37094997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study.
    Lagrèze WA; Küchlin S; Ihorst G; Grotejohann B; Beisse F; Volkmann M; Heinrich SP; Albrecht P; Ungewiss J; Wörner M; Hug MJ; Wolf S; Diem R;
    Lancet Neurol; 2021 Dec; 20(12):991-1000. PubMed ID: 34800417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial-study protocol.
    Diem R; Molnar F; Beisse F; Gross N; Drüschler K; Heinrich SP; Joachimsen L; Rauer S; Pielen A; Sühs KW; Linker RA; Huchzermeyer C; Albrecht P; Hassenstein A; Aktas O; Guthoff T; Tonagel F; Kernstock C; Hartmann K; Kümpfel T; Hein K; van Oterendorp C; Grotejohann B; Ihorst G; Maurer J; Müller M; Volkmann M; Wildemann B; Platten M; Wick W; Heesen C; Schiefer U; Wolf S; Lagrèze WA
    BMJ Open; 2016 Mar; 6(3):e010956. PubMed ID: 26932144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis.
    Sühs KW; Hein K; Sättler MB; Görlitz A; Ciupka C; Scholz K; Käsmann-Kellner B; Papanagiotou P; Schäffler N; Restemeyer C; Bittersohl D; Hassenstein A; Seitz B; Reith W; Fassbender K; Hilgers R; Heesen C; Bähr M; Diem R
    Ann Neurol; 2012 Aug; 72(2):199-210. PubMed ID: 22926853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease Activity and Conversion into Multiple Sclerosis after Optic Neuritis Is Treated with Erythropoietin.
    Sühs KW; Papanagiotou P; Hein K; Pul R; Scholz K; Heesen C; Diem R
    Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27706045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, placebo-controlled trial of adding erythropoietin to intravenous methylprednisolone for the treatment of unilateral acute optic neuritis of unknown or demyelinative origin.
    Shayegannejad V; Shahzamani S; Dehghani A; Dast Borhan Z; Rahimi M; Mirmohammadsadeghi A
    Graefes Arch Clin Exp Ophthalmol; 2015 May; 253(5):797-801. PubMed ID: 25605544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial.
    Raftopoulos R; Hickman SJ; Toosy A; Sharrack B; Mallik S; Paling D; Altmann DR; Yiannakas MC; Malladi P; Sheridan R; Sarrigiannis PG; Hoggard N; Koltzenburg M; Gandini Wheeler-Kingshott CA; Schmierer K; Giovannoni G; Miller DH; Kapoor R
    Lancet Neurol; 2016 Mar; 15(3):259-69. PubMed ID: 26822749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.
    Beck RW; Cleary PA; Anderson MM; Keltner JL; Shults WT; Kaufman DI; Buckley EG; Corbett JJ; Kupersmith MJ; Miller NR
    N Engl J Med; 1992 Feb; 326(9):581-8. PubMed ID: 1734247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis.
    Andorrà M; Alba-Arbalat S; Camos-Carreras A; Gabilondo I; Fraga-Pumar E; Torres-Torres R; Pulido-Valdeolivas I; Tercero-Uribe AI; Guerrero-Zamora AM; Ortiz-Perez S; Zubizarreta I; Sola-Valls N; Llufriu S; Sepulveda M; Martinez-Hernandez E; Armangue T; Blanco Y; Villoslada P; Sanchez-Dalmau B; Saiz A; Martinez-Lapiscina EH
    JAMA Neurol; 2020 Feb; 77(2):234-244. PubMed ID: 31566686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticosteroids for treating optic neuritis.
    Gal RL; Vedula SS; Beck R
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD001430. PubMed ID: 26273799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group.
    Beck RW; Cleary PA; Trobe JD; Kaufman DI; Kupersmith MJ; Paty DW; Brown CH
    N Engl J Med; 1993 Dec; 329(24):1764-9. PubMed ID: 8232485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study.
    Tourbah A; Gout O; Vighetto A; Deburghgraeve V; Pelletier J; Papeix C; Lebrun-Frenay C; Labauge P; Brassat D; Toosy A; Laplaud DA; Outteryck O; Moreau T; Debouverie M; Clavelou P; Heinzlef O; De Sèze J; Defer G; Sedel F; Arndt C
    CNS Drugs; 2018 Jul; 32(7):661-672. PubMed ID: 29808469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial.
    Optic Neuritis Study Group
    Ophthalmology; 2008 Jun; 115(6):1079-1082.e5. PubMed ID: 17976727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietin as an adjunctive treatment for methanol-induced toxic optic neuropathy.
    Pakravan M; Esfandiari H; Sanjari N; Ghahari E
    Am J Drug Alcohol Abuse; 2016 Nov; 42(6):633-639. PubMed ID: 27463192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis.
    Fisher JB; Jacobs DA; Markowitz CE; Galetta SL; Volpe NJ; Nano-Schiavi ML; Baier ML; Frohman EM; Winslow H; Frohman TC; Calabresi PA; Maguire MG; Cutter GR; Balcer LJ
    Ophthalmology; 2006 Feb; 113(2):324-32. PubMed ID: 16406539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amiloride Clinical Trial In Optic Neuritis (ACTION) protocol: a randomised, double blind, placebo controlled trial.
    McKee JB; Elston J; Evangelou N; Gerry S; Fugger L; Kennard C; Kong Y; Palace J; Craner M
    BMJ Open; 2015 Nov; 5(11):e009200. PubMed ID: 26553836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corticosteroids for treating optic neuritis.
    Gal RL; Vedula SS; Beck R
    Cochrane Database Syst Rev; 2012 Apr; 4(4):CD001430. PubMed ID: 22513900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Individual-Level Factors With Visual Outcomes in Optic Neuritis: Secondary Analysis of a Randomized Clinical Trial.
    De Lott LB; Burke JF; Andrews CA; Costello F; Cornblath WT; Trobe JD; Lee PP; Kerber KA
    JAMA Netw Open; 2020 May; 3(5):e204339. PubMed ID: 32379333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optic neuritis treatment trial. One-year follow-up results.
    Beck RW; Cleary PA
    Arch Ophthalmol; 1993 Jun; 111(6):773-5. PubMed ID: 8512477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Treating Acute Optic Neuritis With Bioequivalent Oral vs Intravenous Corticosteroids: A Randomized Clinical Trial.
    Morrow SA; Fraser JA; Day C; Bowman D; Rosehart H; Kremenchutzky M; Nicolle M
    JAMA Neurol; 2018 Jun; 75(6):690-696. PubMed ID: 29507942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.